GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2016 | 12-2015 | 09-2015 | 06-2015 | 03-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 30 | 47 | 42 | 125 | 1,418 |
| TOTAL | $32 | $49 | $44 | $127 | $1,420 |
| Non-Current Assets | |||||
| PPE Net | 5 | 5 | 5 | 5 | 5 |
| TOTAL | $5 | $5 | $5 | $5 | $5 |
| Total Assets | $37 | $54 | $49 | $132 | $1,425 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 8,852 | 7,859 | 2,837 | 1,980 | 1,938 |
| Accounts payable and accrued liabilities | 1,538 | 893 | 968 | 431 | 256 |
| Accrued Expenses | 3,344 | 6,717 | 6,187 | 4,900 | 7,642 |
| Other current liabilities | 4,795 | 33,266 | 11,345 | 13,299 | 39,702 |
| TOTAL | $19,703 | $49,909 | $22,308 | $21,581 | $50,509 |
| Non-Current Liabilities | |||||
| Long Term Debt | 553 | 714 | 2,290 | 1,451 | 849 |
| TOTAL | $553 | $714 | $2,290 | $1,451 | $849 |
| Total Liabilities | $20,256 | $50,623 | $24,598 | $23,032 | $51,358 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 44 | 42 | 600,000 | 600,000 | 600,000 |
| Common Shares | 22 | 2 | 600 | 600 | 596 |
| Retained earnings | -119,734 | -134,417 | -108,304 | -106,612 | -133,472 |
| Other shareholders' equity | -166 | -166 | -166 | -166 | -166 |
| TOTAL | $-20,219 | $-50,569 | $-24,549 | $-22,900 | $-49,933 |
| Total Liabilities And Equity | $37 | $54 | $49 | $132 | $1,425 |